Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDG1901 vs Ozempic in Type 2 Diabetes
NCT06739044Phase 3Completed
- Sponsor
- Huadong Medicine
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Recombinant polypeptide, Biosimilar, Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide biosimilar (HDG1901) in type 2 diabetes mellitus (T2DM), sponsored by Huadong Medicine. Started Sep 2023; status: completed.
02
Drugs
semaglutide biosimilar (HDG1901)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06739044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739044.